These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 324622)

  • 1. Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
    Ahmann DL; O'Connell MJ; Bisel HF; Edmonson JH; Hahn RG; Frytak S
    Cancer Treat Rep; 1977; 61(1):81-2. PubMed ID: 324622
    [No Abstract]   [Full Text] [Related]  

  • 2. 1,2:5,6-Dianhydrogalactitol in advanced breast cancer.
    Hoogstraten B; O'Bryan R; Jones S
    Cancer Treat Rep; 1978 May; 62(5):841-2. PubMed ID: 657167
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma.
    Ahmann DL; Bisel HF; Edmonson JH; Hahn RG; O'Connell MJ; Frytak S
    Cancer Treat Rep; 1976 Nov; 60(11):1681-2. PubMed ID: 1021239
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.
    Perry MC; Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
    Cancer Treat Rep; 1976 Sep; 60(9):1247-50. PubMed ID: 797447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and beta-2'-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. Gastrointestinal Tumor Study Group.
    Cancer Treat Rep; 1985 Jun; 69(6):713-6. PubMed ID: 3926311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I evaluation of dianhydrogalactitol (NSC-132313).
    Haas CD; Stephens RL; Hollister M; Hoogstraten B
    Cancer Treat Rep; 1976 May; 60(5):611-4. PubMed ID: 991150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of dianhydrogalactitol administered Iv in a weekly schedule.
    Vogel CL; Winton EF; Moore MR; Sohner S
    Cancer Treat Rep; 1976 Jul; 60(7):895-901. PubMed ID: 795538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of ICRF-159 in refractory metastatic breast cancer.
    Creech RH; Engstrom PF; Harris DT; Catalano RB; Bellet RE
    Cancer Treat Rep; 1979 Jan; 63(1):111-4. PubMed ID: 369681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adriamycin plus vincristine alone or with dibromodulcitol or ICRF-159 in metastatic breast cancer.
    Cummings FJ; Gelman R; Tormey DC; DeWys W; Glick J
    Cancer Clin Trials; 1981; 4(3):253-60. PubMed ID: 7026074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of razoxane (ICRF-159) in patients with squamous cell carcinoma of the head and neck previously exposed to systemic chemotherapy.
    Shah MK; Engstrom PF; Catalano RB; Paul AR; Bellet RE; Creech RH
    Cancer Treat Rep; 1982 Mar; 66(3):557-8. PubMed ID: 7060043
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I and II studies of cytostatic hexitol derivatives: the role of alkylating metabolites?
    Eckhardt S; Kerpel-Fronius S; Horváth IP; Institoris L
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 2):783-8. PubMed ID: 3985644
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II study of ICRF-159 in non-Hodgkin's lymphomas.
    Flannery EP; Corder MP; Sheehan WW; Pajak TF; Bateman JR
    Cancer Treat Rep; 1978 Mar; 62(3):465-7. PubMed ID: 348318
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II trial of ICRF-187 in squamous cell carcinoma of the head and neck.
    Wheeler RH; Bricker LJ; Natale RB; Baker SR
    Cancer Treat Rep; 1984 Feb; 68(2):427-8. PubMed ID: 6421483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer.
    Eagan RT; Ingle JN; Frytak S; Rubin J; Kvols LK; Carr DT; Coles DT; O'Fallon JR
    Cancer Treat Rep; 1977 Oct; 61(7):1339-45. PubMed ID: 589599
    [No Abstract]   [Full Text] [Related]  

  • 15. Eastern Cooperative Oncology Group phase II studies in advanced measurable colorectal cancer. I. Razoxane, Yoshi-864, piperazinedione, and lomustine.
    Douglass HO; MacIntyre JM; Kaufman J; Von Hoff D; Engstrom PF; Klaassen D
    Cancer Treat Rep; 1985 May; 69(5):543-5. PubMed ID: 2988774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy.
    Bellet RE; Engstrom PF; Catalano RB; Creech RH; Mastrangelo MJ
    Cancer Treat Rep; 1976 Sep; 60(9):1395-7. PubMed ID: 1016973
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II study of dianhydrogalactitol in malignant glioma.
    Espana P; Wiernik PH; Walker MD
    Cancer Treat Rep; 1978 Aug; 62(8):1199-200. PubMed ID: 210944
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of melphalan, ICRF-159, and hydroxyurea in metastatic prostate cancer: a preliminary report.
    Kvols LK; Eagan RT; Myers RP
    Cancer Treat Rep; 1977; 61(2):311-2. PubMed ID: 326400
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer.
    Hahn RG; Bauer M; Wolter J; Creech R; Bennett JM; Wampler G
    Cancer Treat Rep; 1979 Mar; 63(3):513-5. PubMed ID: 371804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and strategy for prevention of anthracycline cardiotoxicity with the bisdioxopiperazine, ICRF-187.
    Green MD
    Pathol Biol (Paris); 1987 Jan; 35(1):49-53. PubMed ID: 3550612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.